General
Preferred name
ISOCARBOXAZID
Synonyms
RO 5-0831 ()
Isocarboxazide ()
NSC-169893 ()
Enerzer ()
RO-5-0831 ()
Isocarboxazida ()
Marplan ()
P&D ID
PD009939
CAS
59-63-2
Tags
available
drug
Approved by
FDA
First approval
1959
Drug indication
Major depressive disorder
Depression
Drug Status
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Isocarboxazid is a monoamine oxidase inhibitor (MAOI).
(GtoPdb)
DESCRIPTION
Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 ¦ÌM for rat brain monoamine oxidase in vitro[1].
PRICE
68
DESCRIPTION
Isocarboxazid is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) belonging to the hydrazine class. It is primarily used to treat mood and anxiety disorders. It is also used for the treatment of Parkinson's disease and other dementia-related disorders. It is also effective in the treatment of major depression, dysthymic disorder, and atypical depression. It blocks the breakdown (oxidative deamination) of biogenic amines by inhibiting MAO, thereby increasing the concentrations of norepinephrine and 5-hydroxytrytamine at central aminergic receptors. It was developed by Validus and has been listed.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Isocarboxazid is a monoamine oxidase inhibitor used to treat enduring and debilitating symptoms of depression following inadequate clinical response to other antidepressant drugs.
(Enamine Bioactive Compounds)
DESCRIPTION
Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.[2] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
38
Molecular Weight
231.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
1.42
TPSA
67.16
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Neuroscience
Neuronal Signaling
MOA
monoamine oxidase
monoamine oxidase inhibitor
Target
MAOA, MAOB
Monoamine Oxidase
Indication
depression
ATC
N06AF01
Toxicity type
hepatic
Therapeutic Class
Antidepressants
Solubility
Acetontrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
Source data
